561 related articles for article (PubMed ID: 10776836)
1. Nelfinavir: an update on its use in HIV infection.
Bardsley-Elliot A; Plosker GL
Drugs; 2000 Mar; 59(3):581-620. PubMed ID: 10776836
[TBL] [Abstract][Full Text] [Related]
2. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
3. Nelfinavir. A review of its therapeutic efficacy in HIV infection.
Jarvis B; Faulds D
Drugs; 1998 Jul; 56(1):147-67. PubMed ID: 9664204
[TBL] [Abstract][Full Text] [Related]
4. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.
Figgitt DP; Plosker GL
Drugs; 2000 Aug; 60(2):481-516. PubMed ID: 10983742
[TBL] [Abstract][Full Text] [Related]
5. Saquinavir: a review of its use in boosted regimens for treating HIV infection.
Plosker GL; Scott LJ
Drugs; 2003; 63(12):1299-324. PubMed ID: 12790697
[TBL] [Abstract][Full Text] [Related]
6. Delavirdine: a review of its use in HIV infection.
Scott LJ; Perry CM
Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
[TBL] [Abstract][Full Text] [Related]
7. Nelfinavir: a review of its use in the management of HIV infection.
Perry CM; Frampton JE; McCormack PL; Siddiqui MA; Cvetković RS
Drugs; 2005; 65(15):2209-44. PubMed ID: 16225378
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
9. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
[TBL] [Abstract][Full Text] [Related]
10. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).
Pellegrin I; Breilh D; Montestruc F; Caumont A; Garrigue I; Morlat P; Le Camus C; Saux MC; Fleury HJ; Pellegrin JL
AIDS; 2002 Jul; 16(10):1331-40. PubMed ID: 12131209
[TBL] [Abstract][Full Text] [Related]
11. Nelfinavir mesylate: a protease inhibitor.
Pai VB; Nahata MC
Ann Pharmacother; 1999 Mar; 33(3):325-39. PubMed ID: 10200859
[TBL] [Abstract][Full Text] [Related]
12. Simplifying drug regimens.
HIV Hotline; 1998 Mar; 8(1):11. PubMed ID: 11365353
[TBL] [Abstract][Full Text] [Related]
13. Amprenavir: a review of its clinical potential in patients with HIV infection.
Noble S; Goa KL
Drugs; 2000 Dec; 60(6):1383-410. PubMed ID: 11152018
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
Starr SE; Fletcher CV; Spector SA; Yong FH; Fenton T; Brundage RC; Manion D; Ruiz N; Gersten M; Becker M; McNamara J; Mofenson LM; Purdue L; Siminski S; Graham B; Kornhauser DM; Fiske W; Vincent C; Lischner HW; Dankner WM; Flynn PM
N Engl J Med; 1999 Dec; 341(25):1874-81. PubMed ID: 10601506
[TBL] [Abstract][Full Text] [Related]
15. [HIV genotypic mutation selectively induced by the protease inhibitor nelfinavir at codon 30. Case series and consequences for antiretroviral management].
Manfredi R; Calza L
Infez Med; 2002 Sep; 10(3):151-6. PubMed ID: 12704265
[TBL] [Abstract][Full Text] [Related]
16. Abacavir: a review of its clinical potential in patients with HIV infection.
Hervey PS; Perry CM
Drugs; 2000 Aug; 60(2):447-79. PubMed ID: 10983741
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P
Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
[TBL] [Abstract][Full Text] [Related]
18. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C; Tribut O
Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
[TBL] [Abstract][Full Text] [Related]
19. Emergence of drug resistance mutations in a group of HIV-infected children taking nelfinavir-containing regimens.
Fitzgibbon JE; Gaur S; Walsman SM; Janahi M; Whitley-Williams P; John JF
AIDS Res Hum Retroviruses; 2001 Sep; 17(14):1321-8. PubMed ID: 11602042
[TBL] [Abstract][Full Text] [Related]
20. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
